Geographic and Racial Disparities in Chimeric Antigen Receptor –T Cells and Bi-specific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma

We investigate the geographical and racial disparities in accessing CAR-T and bispecific antibodies trials for DLBCL. ClinicalTrials.gov was searched, and 75 trials with at least one open site in the US were included. 2020 US Census Bureau data was used to obtain data on race and ethnicity. SPSS version 26 was used for analysis. There were 62 CAR-T and 13 bispecific antibodies trials with 6221 enrolled or expected to enroll patients. 85% of the clinical trials were only open in the US, and the majority 64% were pharmaceutical-funded.  There were 126 unique study sites distributed over 31 states with 11 (0-51) mean number of trials per state and 4.5 (1-26) and 4.4 (1-24) mean number of CAR-T and bispecific antibodies trials per site, respectively.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research